TerminatedPHASE1, PHASE2NCT02282358

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Studying Diffuse large B-cell lymphoma with chronic inflammation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Andrew Zelenetz, MD, PhD, M.D
Memorial Sloan Kettering Cancer Center
Intervention
Mocetinostat(drug)
Enrollment
7 target
Eligibility
18 years · All sexes
Timeline
20142023

Study locations (1)

Collaborators

MethylGene Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02282358 on ClinicalTrials.gov

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

See all trials for Diffuse large B-cell lymphoma with chronic inflammation

← Back to all trials